In January 2013 the U.S. Food and Drug Administration cut the recommended dose of the nation’s most popular sleep drug, Ambien, in half for women but not for men. The FDA had determined that 15 percent of the 5.7 million women using zolpidem products (the active ingredient in Ambien) were experiencing driving impairment eight hours after taking the drug, compared with 3 percent of the 3.5 million male zolpidem users.